Status:
COMPLETED
Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis
Lead Sponsor:
Zagazig University
Conditions:
Hypersensitivity Pneumonitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study aims to evaluate the efficacy of pirfenidone in chronic hypersensitivity pneumonitis. This study included 40 adult patients (≥ 18 years) with a diagnosis of chronic progressive hypersensiti...
Detailed Description
Rationale The present data about the treatment of CHP are few and largely based on observational studies and expert opinion. It is suggested that pirfenidone may slow disease progression in cases of C...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years old with a diagnosis of chronic progressive Hypersensitivity pneumonitis:
- \>10% extent of fibrosis (eg, reticulation) on high-resolution CT (HRCT) scan
- Absolute decline in FVC% predicted \>5% within the previous 6 months despite conventional treatment.
Exclusion
- Pregnancy or breastfeeding period
- Patients with peptic ulcer, severe hepatic disease, severe kidney disease, severe cardiac disease, and patients with other chronic pulmonary diseases.
- Presence of active infection
- History of alcohol or drugs abuse
- Active smokers
Key Trial Info
Start Date :
December 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04675619
Start Date
December 1 2019
End Date
June 30 2020
Last Update
December 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eman Shebl
Zagazig, Egypt, 44555